(RTTNews) - Picard Medical Inc. (PMI) is slated to present full data on its next-generation artificial heart at the CSI Focus D-HF 2025 conference in Frankfurt, Germany, on December 6, 2025.
The presentation will highlight the first comprehensive pre-clinical results from the fully implantable Emperor Total Artificial Heart (TAH).
Picard Medical is the parent company of SynCardia Systems LLC, the maker of the world's first total artificial heart approved by both the U.S. FDA and Health Canada.
The presentation builds on SynCardia's recent milestone of completing the first in vivo implantations of the emperor TAH. Early testing showed stable hemodynamics, physiologic preload sensitivity, and afterload independence ¬- behaviours that replicate the Frank-Starling response of a natural human heart.
The company noted that the Emperor platform is designed to expand patient options by offering a fully implantable system with improved performance and patient independence.
Revenue from the SynCardia Total Artificial Heart (STAH) platform was $3.93 million in the first nine months of 2025, up 11% from $3.56 million in the same period of 2024.
PMI closed yesterday's trading at $3.69, up 82.67%. In premarket trading today, the stock is down over 7% at $3.45.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
